Posters & Presentations

PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. Verstovsek S, et al. 57th American Society of Hematology (ASH) Annual Meeting & Exposition, December 2015.

Interview with Dr. Srdan Verstovsek, Principal Investigator for Promedior's Myelofibrosis Trial
57th American Society of Hematology (ASH) Annual Meeting in Orlando

Outcomes in Myelofibrosis Patients Completing 24 and 36 Weeks of Treatment with PRM-151. Verstovsek S, et al. Third Annual Meeting of the Society of Hematologic Oncology (SOHO), September 2015.

Bone Marrow Fibrosis by WHO Grade and Quantitative Image Analysis is Reduced by PRM-151 in Patients with Myelofibrosis and Associated with Improved Bone Marrow Morphology and Increased Platelet Counts. Pozdnyakova O, et al. 20th Congress of European Hematology Association (EHA), June 2015.

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. Verstovsek S, et al. 56th American Society of Hematology (ASH) Annual Meeting & Exposition, December 2014.

Structural and Functional Quanitative Imaging Techniques are Complimentary in Retrospective Analysis of PRM-151 Data in Idiopathic Pulmonary Fibrosis (IPF). Erasmus MC, et al. 18th International Colloquium on Lung and Airway Fibrosis (ICLAF 2014), September 2014.

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. Verstovsek S, et al. 19th Congress of European Hematology Association (EHA), June 2014.

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. Verstovsek S, et al. American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, June 2014.

PRM-151 in Idiopathic Pulmonary Fibrosis and Myelofibrosis. Trehu EG, et al. Keystone Symposia, March 2014.

Exploratory Efficacy Evaluation of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis. Trehu EG, et al. PFF Summit, December 2013.

Recombinant Pentraxin-2 Therapy Attenuates the Progression of Alport Nephropathy in Collagen IVα(3) Deficient Mice. Nakagawa N, et al. American Society of Nephrology Annual Meeting, November 2013.

A Phase I Study of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis. Van den Blink B, et al. ATS, May 2013.















Pentraxin-2 mechanism of action
 
Pentraxin-2 therapeutics act as a master regulator of the complex fibrosis cascade, promoting healing and preventing disease progression. Learn More >